- Previous Close
7.65 - Open
7.50 - Bid 7.35 x 50000
- Ask 7.40 x 50000
- Day's Range
7.50 - 7.50 - 52 Week Range
7.50 - 11.10 - Volume
73 - Avg. Volume
13 - Market Cap (intraday)
2.304B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.17 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
amicusrx.comRecent News: AM6.F
View MorePerformance Overview: AM6.F
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AM6.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AM6.F
View MoreValuation Measures
Market Cap
2.31B
Enterprise Value
2.49B
Trailing P/E
--
Forward P/E
454.55
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.77
Price/Book (mrq)
13.11
Enterprise Value/Revenue
5.11
Enterprise Value/EBITDA
91.79
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.62%
Return on Assets (ttm)
2.72%
Return on Equity (ttm)
-31.68%
Revenue (ttm)
528.3M
Net Income Avi to Common (ttm)
-56.11M
Diluted EPS (ttm)
-0.17
Balance Sheet and Cash Flow
Total Cash (mrq)
249.95M
Total Debt/Equity (mrq)
228.63%
Levered Free Cash Flow (ttm)
5.41M